Cultured psoriatic fibroblasts from involved and uninvolved sites have a partial but not absolute resistance to the proliferationinhibition activity of 1,25-dihydroxyvitamin D3 
Psoriasis is a common disease of the skin affecting about 1-3% ofthe population ofthe world (1) . Although this chronic debilitating disease has been recognized for several centuries, little is known about its etiology. Psoriasis is thought to be principally a disease of the epidermis that causes a disruption in the normal events of cell maturation and proliferation (1) . It is characterized by an increase in the number ofbasal cells in the epidermis and a reduced turnover time of the epidermis from the normal of 26-27 days to 4 days (1).
1,25-Dihydroxyvitamin D3 (1,25-(OH)2-D3), the active form of vitamin D3, is a potent inducer of differentiation and maturation of normal and tumor cells that possess cytosolic and nuclear receptors for the hormone (2) (3) (4) (5) (6) (7) . In addition, the skin is now recognized as a target organ for 1,25-(OH)2-D3. Autoradiographic studies in rats showed localization of 1,25-(OH)2-[3H]D3 in the cells of the root sheath of the hair follicles and in the stratum basale (8) , and culture studies showed high-affinity low-capacity receptors for this hormone in human and rodent fibroblasts (9-11) and keratinocytes (12, 13) . 1,25-(OH)2-D3 stimulates 25-hydroxyvitamin D3-24-hydroxylase activity (11, 14) and decreases cellular proliferation (10) in a dose-dependent manner in cultured human fibroblasts that possess the 1,25-(OH)2-D3 receptor but has no effect on cultured fibroblasts from patients with vitamin D-dependent rickets, type II, which either lack or have a defective 1,25-(OH)2-D3 receptor (10, 11, 14) . 1,25-(OH)2-D3 also induces morphologic differentiation of cultured mouse (12) and human (13) keratinocytes. In the presence of 0.01 ,uM 1,25-(OH)2-D3, cultured human basal cells differentiate into less-dense squamous and cornified cells. In addition, this hormone increases transglutaminase activity and 25-hydroxyvitamin D3-24-hydroxylase in these cells (13) .
Because psoriasis is a disorder of differentiation and because 1,25-(OH)2-D3 is such a potent hormone for stimulating the maturation of dermal and epidermal cells, we examined the effect of this hormone on cultured fibroblasts from six patients with psoriasis.
METHODS
Fibroblasts were isolated from 4-mm punch biopsies from uninvolved and involved areas on the backs of six patients with psoriasis and from age-matched controls. The fibroblasts were isolated and cultured as described (10) . Cultured fibroblasts (2.5 x 105 cells) were exposed either to 0.0001, 0.01, 10, or 100 ,uM of 1,25-(OH)2-D3 or to ethanol vehicle (0.01%). Analyses of cell number and the 1,25-(OH)2-D3 receptor by sucrose density gradient, saturation binding, and DNA-cellulose chromatography were performed as described (10) . Protein concentrations were determined by the method of Lowry et al. (15) . Binding affinity (Kd) and capacity (nfmax) were obtained from saturation-binding curves and were estimated by the method of Scatchard (16) .
RESULTS
Cultured normal human fibroblasts incubated with 1,25-(OH)2-D3 demonstrated a dose-dependent inhibition of cell proliferation (Fig. LA) . However, when cultured fibroblasts obtained from a biopsy of an uninvolved area from a psoriatic patient were incubated with 1,25-(OH)2-D3 at 0.0001, 0.01, or 1 jLM, no effect on cell proliferation was observed when they were compared with the control group (Fig. 1B) . When these cells were exposed to 10 and 100 ,tM of 1,25-(OH)2-D3, a dose-dependent inhibition of cell proliferation was observed, suggesting that psoriatic fibroblasts have a partial but not absolute resistance to the hormone. Similar results were obtained for the cultured dermal fibroblasts from involved and uninvolved skin from the other five patients.
We examined whether the cause for the partial resistance of dermal psoriatic fibroblasts was due to a defect in the recognition or binding capacity ofthe cells for 1,25-(OH)2-D3. disease. There are various treatments for this disorder including steroids, cytotoxic drugs, and psoralen in combination with exposure to ultraviolet-A radiation (PUVA), but to date there is not an effective and safe cure (1) .
It has been recognized that there are several abnormalities in the dermis of patients with psoriasis. Dilated tortuous capillaries are often observed by histology (18) and there is less cross-linked collagen and a greater content of glycosaminoglycans (19, 20) . Recently, Priestley and Adams (21) reported slightly quicker outgrowth of fibroblasts from psoriatic skin explants from involved and uninvolved forearm skin when compared to the outgrowth from control skin and that psoriatic fibroblasts were abnormally dependent on serum for anchorage. They concluded that their findings were most compatible with a hyperproliferative reaction of both the epidermis and dermis to extracutaneous, perhaps vascular stimulation.
Our observation that cultured fibroblasts from uninvolved sites have a partial resistance to the cell-proliferation-inhibition activity of 1,25-(OH)2-D3 suggests that there may be a biochemical defect that is inherent in the dermal fibroblasts of psoriatic patients. However, this defect is not due to some abnormality in the cellular uptake of 1,25-(OH)2-D3 or its recognition by its cytosolic or nuclear receptors. Probably, the defect is at the level of the nuclear recognition of the unlikely that such a biochemical defect is caused by some extracutaneous mechanism.
Because fibroblasts can be obtained quickly and cultured easily from a small biopsy, we chose to evaluate only the dermal fibroblasts of the psoriatic patients. We would predict, however, that cultured psoriatic keratinocytes also would have a partial resistance to the differentiating activity of 1,25-(OH)2-D3 because the receptor activity and biologic response of cultured dermal fibroblasts are predictors of the receptor activity and biologic response of cultured epidermal cells (10, 13) . If our observations are confirmed and if this defect is seen in a majority of patients with psoriasis, the evaluation of the responsiveness of cultured dermal fibroblasts to 1,25-(OH)2-D3 may be of great diagnostic value.
Our observation that a 1000-times-higher concentration of 1,25-(OH)2-D3 was needed to inhibit proliferation of cultured 10 ,uM had no effect on cell proliferation of normal (10) or cultured psoriatic fibroblasts (data not shown), and (ii) 1,25-(OH)2-D3 at 10 and 100 gM had no effect on the proliferation of cultured fibroblasts from a patient with vitamin D-dependent rickets, type II, which are cells lacking receptor activity for the hormone (data not shown).
Whether 1,25-(OH)2-D3 will be useful therapeutically in treating psoriasis remains to be determined. However, even if 1,25-(OH)2-D3 does prove to be of some therapeutic value, it may not be practical to treat psoriatic patients with high doses of 1,25-(OH)2-D3 in an attempt to pharmacologically restore epidermal mitotic activity to normal because this hormone is a potent calciotropic hormone that can cause hypercalciuria and hypercalcemia. However, the recent preliminary report that A22-la,25,26-trihydroxyvitamin D3 (22) is able to induce maturation of tumor cell lines while having little biologic activity related to calcium metabolism may provide a novel approach to the treatment of this enigmatic disease.
Therefore, our observation that cultured fibroblasts from psoriatic skin have a partial but not absolute resistance to 1,25-(OH)2-D3 offers a new evaluation of the cause of this disorder and possibly a unique approach to its treatment.
